TY - JOUR
T1 - Engineering therapeutic antibodies targeting G-protein–coupled receptors
AU - Jo, Migyeong
AU - Jung, Sang Taek
N1 - Funding Information:
This work was supported by a grant from the National R&D Program for Cancer Control, Ministry of Health and Welfare, Republic of Korea (1420160), the Basic Science Research Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Science, ICT and Future Planning (2013R1A1A1004576), and the Bio & Medical Technology Development Program of the National Research Foundation (NRF) funded by the Korean government (MSIP; 2014M3A9D9069609).
Publisher Copyright:
© 2016 KSBMB. All rights reserved 2092-6413/16.
PY - 2016/2
Y1 - 2016/2
N2 - G-protein–coupled receptors (GPCRs) are one of the most attractive therapeutic target classes because of their critical roles in intracellular signaling and their clinical relevance to a variety of diseases, including cancer, infection and inflammation. However, high conformational variability, the small exposed area of extracellular epitopes and difficulty in the preparation of GPCR antigens have delayed both the isolation of therapeutic anti-GPCR antibodies as well as studies on the structure, function and biochemical mechanisms of GPCRs. To overcome the challenges in generating highly specific anti-GPCR antibodies with enhanced efficacy and safety, various forms of antigens have been successfully designed and employed for screening with newly emerged systems based on laboratory animal immunization and high-throughput-directed evolution.
AB - G-protein–coupled receptors (GPCRs) are one of the most attractive therapeutic target classes because of their critical roles in intracellular signaling and their clinical relevance to a variety of diseases, including cancer, infection and inflammation. However, high conformational variability, the small exposed area of extracellular epitopes and difficulty in the preparation of GPCR antigens have delayed both the isolation of therapeutic anti-GPCR antibodies as well as studies on the structure, function and biochemical mechanisms of GPCRs. To overcome the challenges in generating highly specific anti-GPCR antibodies with enhanced efficacy and safety, various forms of antigens have been successfully designed and employed for screening with newly emerged systems based on laboratory animal immunization and high-throughput-directed evolution.
UR - http://www.scopus.com/inward/record.url?scp=84962832391&partnerID=8YFLogxK
U2 - 10.1038/EMM.2015.105
DO - 10.1038/EMM.2015.105
M3 - Article
C2 - 26846450
AN - SCOPUS:84962832391
SN - 1226-3613
VL - 48
JO - Experimental and Molecular Medicine
JF - Experimental and Molecular Medicine
IS - 2
M1 - e207
ER -